Fig. 3: Visugromab in combination with nivolumab induces remissions in a fraction of anti-PD-1/PD-L1 relapsed or refractory last-line NSCLC and UC. | Nature

Fig. 3: Visugromab in combination with nivolumab induces remissions in a fraction of anti-PD-1/PD-L1 relapsed or refractory last-line NSCLC and UC.

From: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Fig. 3: Visugromab in combination with nivolumab induces remissions in a fraction of anti-PD-1/PD-L1 relapsed or refractory last-line NSCLC and UC.

a,b, Swimmer plot for patients with NSCLC (a) and UC (b) illustrating response assessment according to RECIST 1.1 and time on study. Patients with PR or CR are highlighted in light and dark green, respectively; patients with SD but decrease in target lesion size (>5%; tumour shrinkage) are highlighted in blue. Light blue indicates SD, and PD is depicted in grey (X indicates detection of PD). Patients who received radiotherapy on treatment are not evaluable (NE (post RT)) anymore, which is indicated by a hatched fill. Scans were performed approximately every 8 weeks.

Back to article page